Also known as Lys-Glu-Asp · KED tripeptide
Synthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator.
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) in the Khavinson short-peptide bioregulator series, studied for tissue-specific effects on the vascular wall and endothelium.
Vesugen (Lys-Glu-Asp) is the vascular-targeted member of the defined short-peptide bioregulator family. Each peptide in the series is associated with a specific tissue; Vesugen is framed around the blood-vessel wall and endothelial function.
Reported research examined endothelial markers and vascular-tone regulation in cell and animal models, consistent with the class hypothesis of tissue-selective transcriptional modulation. Evidence is concentrated in the originating research tradition, independent replication is limited, and it is not FDA-approved.
Proposed gene-regulatory modulation of vascular/endothelial gene expression.
Behind every vial of Vesugen is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Vesugen, specifically, is brought into being.
On paper, Vesugen weighs in at roughly 390.4 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Vesugen means roughly 3 coupling cycles on the synthesizer — one protected residue added at a time, which is also 3 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Vesugen plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Vesugen proves itself: identity confirmed by mass spectrometry against its ~390.4 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Vesugen — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Vesugen to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Vesugen is a synthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator in the Khavinson short-peptide series.
The blood-vessel wall and endothelium — each bioregulator in the series is framed around a specific target tissue.
It is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewRecombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.